ARS Pharmaceuticals Inc (NASDAQ:SPRY)
| 4.94 Delayed Data As of Dec 01 |  +0.11 / +2.28%Today’s Change | 2.55 Today|||52-Week Range 9.65 | -42.09% Year-to-Date |
Largest transactions by value over
| Name | Type | Date | Shares traded | Share price | Transaction value | Since transaction |
|---|---|---|---|---|---|---|
Orbimed Advisors Private Equity Director |  Buy | 8/29/2023 | 500,000 | $6.20 | $3.1M | -30.18% |
Orbimed Advisors Private Equity Director | Buy | 8/29/2023 | 500,000 | $6.20 | $3.1M | -30.18% |
Shawver Laura K Director |  Sale | 9/01/2023 | 100,000 | $7.71 | $771.0K | -30.38% |
Shawver Laura K Director | Sale | 6/01/2023 | 73,059 | $6.80 | $496.8K | -27.95% |
Shawver Laura K Director | Sale | 5/08/2023 | 57,100 | $6.16 | $351.7K | -17.64% |
Shawver Laura K Director | Sale | 8/02/2023 | 36,281 | $7.09 | $257.2K | -29.64% |
Shawver Laura K Director | Sale | 5/09/2023 | 42,900 | $5.31 | $227.8K | -3.88% |
Shawver Laura K Director | Sale | 6/02/2023 | 26,941 | $6.95 | $187.2K | -31.63% |
Shawver Laura K Director | Sale | 8/03/2023 | 26,107 | $7.01 | $183.0K | -29.29% |
Fitzpatrick Alexander A Chief Legal Officer | Buy | 9/29/2023 | 46,258 | $3.78 | $174.9K | +30.95% |
Page of 3